Digistain provides an MHRA-cleared, UKCA-marked tumour profiling technology to assess the 10-year recurrence risk for ER+ breast cancer patients treated with endocrine therapy. This AI-enabled solution rapidly analyzes biopsy spectral signatures, generating a prognostic score in under one hour. The technology offers clinicians actionable insights to personalize treatment and avoid unnecessary adjuvant chemotherapy at a lower cost than traditional genomic assays.
Funding
$125K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional breast cancer risk stratification methods are slow, expensive, and subjective, often taking weeks to deliver results and relying on costly reagents and manual wet-lab processes. This can lead to delays in treatment decisions and potentially unnecessary chemotherapy for some patients.
Solution
Digistain offers a rapid, AI-enabled tumor profiling technology that assesses the 10-year risk of breast cancer recurrence in post-surgery patients. Using infrared scanning, Digistain captures a unique spectral signature from each biopsy, generating over 10,000 data points that reflect the individual biology of the patient. This data is then analyzed using artificial intelligence to calculate a Digistain Prognostic Score, providing clinicians with actionable insights in under an hour. The technology enables personalized treatment plans, potentially reducing unnecessary chemotherapy while integrating seamlessly with existing clinical workflows. Digistain is MHRA-cleared and UKCA-marked for predicting recurrence risk in Stage I-II, HER2-, ER+ invasive breast cancer patients with up to 3 positive lymph nodes treated with adjuvant endocrine therapy alone.
Target Audience
The primary target audience includes oncologists and clinicians treating Stage I-II, HER2-, ER+ invasive breast cancer patients with up to 3 positive lymph nodes, as well as hospitals and healthcare systems seeking to improve the speed and accuracy of breast cancer risk assessment.
Features
- Optical scan technology captures a unique spectral signature from each biopsy
- AI-powered analysis of imaging data to calculate a Digistain Prognostic Score
- Rapid results in under 1 hour, significantly faster than traditional methods
- Predictive equivalence to traditional genomic risk scoring analytics
- Seamless integration with existing clinical workflows
- Clear insights on the likelihood of breast cancer recurrence within the next 10 years
- Cost-effective solution enabling broader access to recurrence prediction tests